Sugi Predict

Sugi Predict / Compounds / SCHEMBL3868205

SCHEMBL3868205

SCHEMBL3868205

CCOC(=O)C(F)C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.42
▸ LMNA P02545 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ GAA P10253 2/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MGAM O43451 1/20 0.39
▸ SI P14410 1/20 0.39
▸ MGAM2 Q2M2H8 1/20 0.39
▸ SOAT1 P35610 1/20 0.39
▸ TRPA1 O75762 1/20 0.36
▸ CPB2 Q96IY4 1/20 0.35
▸ CYP4F2 P78329 1/20 0.34
▸ CYP4A11 Q02928 1/20 0.34
▸ HDAC4 P56524 2/20 0.34
▸ HDAC6 Q9UBN7 2/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HTT P42858 2/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PIN1 Q13526 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5638431 0.82 ALDH1A1 (0.39) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL14430320 0.82 ALDH1A1 (0.39) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL9936838 0.81 ALDH1A1 (0.50) ALDH1A1HSD17B10GAA
SCHEMBL765474 0.81 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL2865660 0.80 ALDH1A1 (0.37) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL28896061 0.79 ALDH1A1 (0.36) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL9936545 0.78 — —
SCHEMBL20473345 0.78 ALDH1A1 (0.43) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL14715925 0.78 ALDH1A1 (0.43) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL8651390 0.77 NAAA (0.38) ALDH1A1GAAMGAMSIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598413-B2 Process for producing fluorine-containing alkylsulfonylaminoethyl α-substituted acrylate CENTRAL GLASS COMPANY, LIMITED (JP) 2009-10-06 — — US claimed
US-20090069595-A1 Process for Producing Fluorine-Containing Alkylsulfonylaminoethyl Alpha-Substituted Acrylate CENTRAL GLASS COMPANY, LIMITED (JP) 2009-03-12 — — US claimed
EP-3522288-B1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY CELL, AND MODULE DAIKIN IND LTD (JP) 2025-05-14 — — EP disclosed
US-11813278-B2 Highly active compounds against COVID-19 Atea Pharmaceuticals, Inc. (US) 2023-11-14 — — US disclosed
US-11813278-B2 Highly active compounds against COVID-19 Atea Pharmaceuticals, Inc. (US) 2023-11-14 — — US disclosed
EP-4234565-A2 HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 ATEA Pharmaceuticals, Inc. (US) 2023-08-30 — — EP disclosed
US-11738038-B2 Highly active compounds against COVID-19 Atea Pharmaceuticals, Inc. (US) 2023-08-29 — — US disclosed
US-11738038-B2 Highly active compounds against COVID-19 Atea Pharmaceuticals, Inc. (US) 2023-08-29 — — US disclosed
US-11532838-B2 Nonaqueous electrolyte solution and nonaqueous electrolyte battery KANTO DENKA KOGYO CO., LTD. (JP) 2022-12-20 — — US disclosed
CN-108242559-B Electrolyte solution, electrochemical device, lithium ion secondary battery, and assembly 大金工业株式会社 2022-06-07 — — CN disclosed
CN-110062976-B Electrolyte solution, electrochemical device, lithium ion secondary battery, and module 大金工业株式会社 2022-03-15 — — CN disclosed
US-20200235432-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY KANTO DENKA KOGYO CO.,LTD. (JP) 2020-07-23 — — US disclosed
EP-3522288-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY CELL, AND MODULE Daikin Industries, Ltd. (JP) 2019-08-07 — — EP disclosed
US-20180183097-A1 ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2018-06-28 — — US disclosed
US-20180048024-A1 ELECTROLYTIC SOLUTION THE UNIVERSITY OF TOKYO (JP) 2018-02-15 — — US disclosed
CN-107408736-A Electrolyte solution 国立大学法人东京大学 2017-11-28 — — CN disclosed
CN-106278887-A A kind of synthetic method of 2,3,3,3 tetrafluoro propionic esters 赵满良 2017-01-04 — — CN disclosed
US-7598413-B2 Process for producing fluorine-containing alkylsulfonylaminoethyl α-substituted acrylate CENTRAL GLASS COMPANY, LIMITED (JP) 2009-10-06 — — US disclosed
US-20090069595-A1 Process for Producing Fluorine-Containing Alkylsulfonylaminoethyl Alpha-Substituted Acrylate CENTRAL GLASS COMPANY, LIMITED (JP) 2009-03-12 — — US disclosed
EP-0554025-A2 Fluorinated cyclobutyl purines and pyrimidines E.R. SQUIBB & SONS, INC. (US) 1993-08-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180183097-A1 ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE SLC9A1, CA11, CA1 ALDH1A1 1897/4885LMNA 1460/4885HSD17B10 1159/4885
US-11813278-B2 Highly active compounds against COVID-19 PNP, ACE2, MTAP ALDH1A1 2718/4885LMNA 3718/4885HSD17B10 3704/4885
US-11738038-B2 Highly active compounds against COVID-19 PNP, ACE2, MTAP ALDH1A1 2718/4885LMNA 3718/4885HSD17B10 3704/4885
US-20090069595-A1 Process for Producing Fluorine-Containing Alkylsulfonylaminoethyl Alpha-Substituted Acrylate AFF1, AFF2, AFF4 ALDH1A1 3874/4885LMNA 917/4885HSD17B10 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.